Soleno Therapeutics (SLNO) Receivables - Other (2018 - 2019)

Soleno Therapeutics (SLNO) reported Receivables - Other of $9000.0 for Q3 2019, down 50.0% quarter-over-quarter from $18000.0 in Q2 2019.

Soleno Therapeutics (SLNO) Receivables - Other (2018 - 2019) Analysis & Trends

Soleno Therapeutics (SLNO) has 2 years of Receivables - Other data on file, last reported at $9000.0 in Q3 2019.

Receivables - Other for Q3 2019 came in at $9000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2019 was $9000.0 (changed N/A YoY), and the FY2018 annual result was $64000.0, changed N/A from the prior year.
Receivables - Other declined to $9000.0 in Q3 2019 per SLNO's latest filing, from $18000.0 in the prior quarter.
Over five years, Receivables - Other peaked at $72000.0 in Q1 2019 and troughed at $9000.0 in Q3 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Soleno Therapeutics	2.76 Bn	2.51 Bn	93.41 Mn

Download Data